Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Agilent Buys Dow's Oligonucleotide Assets

May 12, 2008 | A version of this story appeared in Volume 86, Issue 19

Agilent Technologies has purchased the nucleic acid manufacturing assets of Dowpharma for an undisclosed sum. Agilent, which supplies measurement equipment and other technologies for life sciences research, entered the nucleic acid contract manufacturing arena in 2006 with the purchase of a 33,500-sq-ft current Good Manufacturing Practice-certified facility in Boulder, Colo., from SynPro. The new assets, including large-scale nucleic acid synthesis, purification, and drying capacity from Dow's discontinued oligonucleotide business, will be moved from Midland, Mich. They are due to come on-line in Boulder at the end of 2008.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.